Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein

Summary

The overall goal of this protocol is to: Evaluate \[18F\]UCB-2897 as an α-synuclein targeted radiopharmaceutical. The primary objective is: • Confirm a specific α -synuclein signal with \[18F\]UCB-2897 in participants with PD and/or MSA relative to healthy volunteers Secondary and exploratory objectives are: * Determine the safety and tolerability of microdose \[18F\]UCB-2897 * Evaluate preliminary dosimetry of \[18F\]UCB-2897 Additional exploratory objectives are: * Determine the pharmacokinetics / metabolism of \[18F\]UCB-2897 * Determine the optimal imaging protocol for \[18F\]UCB-2897

Timeline

Start

2022-01-31

Primary completion

2023-10-25

Completion

2023-10-25

Drugs

Indications